



Remarks

Claims 1-9 are pending in the subject application. In the most recent Office Action, a restriction requirement was issued in this matter. Claims 1-9 are currently before the examiner with claims 10-21 withdrawn from consideration. Favorable consideration of the claims in view of this response, and in view of the remarks set forth herein, is earnestly solicited.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§1.16 or 1.17 as required by this paper to Deposit Account No. 50-2626.

Respectfully submitted,

Dated: December 21, 2004

Christopher E. Olson

Christopher E. Olson, Patent Agent

Registration No. 55,510

Transform Pharmaceuticals, Inc.

29 Hartwell Avenue

Lexington, MA 02421

Phone No.: 781-674-7948

Fax No.: 781-863-7208